Minprog (Alprostadil)

Alprostadil binds to prostaglandin receptors on vascular smooth muscle, activating adenylate cyclase and raising intracellular cyclic AMP. The rise in cAMP causes smooth‑muscle relaxation, leading to vasodilation and inhibition of platelet aggregation, which together increase blood flow to the targeted area.

The dosage of Minprog is individualized by the prescribing clinician based on the specific indication, patient weight, and clinical response. Healthcare professionals determine the appropriate amount and infusion rate, and patients should follow the prescriber’s instructions without alteration.

Safety data for alprostadil in pregnancy and lactation are limited. It should only be used when clearly needed and after a careful risk‑benefit assessment by the treating physician. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their healthcare provider.

To request Minprog, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required), and necessary import documentation.

Compared with other vasodilators such as nitroglycerin, alprostadil has a distinct mechanism that directly mimics prostaglandin E1, offering potent smooth‑muscle relaxation and platelet‑inhibiting effects. Its clinical use is more focused on maintaining ductus arteriosus patency and treating peripheral arterial disease, whereas nitroglycerin is commonly used for angina.

Minprog should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and discard any solution that appears discolored or contains particles.

Minprog is administered intravenously by a qualified healthcare professional. The solution is typically infused over a controlled period, with the rate and total dose determined by the prescriber based on the patient’s condition and response.

The most serious risks include severe hypotension, myocardial infarction, pulmonary edema, and allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of cardiovascular compromise and any hypersensitivity during and after infusion.

Minprog is contraindicated in patients with known hypersensitivity to alprostadil or any component of the formulation, those with uncontrolled severe hypotension, and individuals receiving incompatible vasodilators without appropriate monitoring. Clinicians should also exercise caution in patients with recent myocardial infarction or unstable cardiac conditions.